The objective of this study is to genetically engineer macrophages (Mf) for biological activation and evaluate their anti-tumor activity in a tumor-bearing mouse model. Mouse peritoneal Mf were incubated on the surface of a culture dish which had been coated with the complex of a cationized dextran and luciferase plasmid DNA complex plus a cell adhesion protein, Pronectin for gene transfection (reverse transfection). When compared with the conventional transfection where Mf were transfected in the medium containing the complex, the level of gene expression by the reverse method was significantly high and the time period of gene expression was prolonged. Confocal microscopic observation revealed that the plasmid DNA was localized in the cell nucleus to a higher extent by the reverse transfection method. Following the reverse transfection of Mf by the plasmid DNA of a hepatocyte growth factor antagonist (NK4) complexed with the cationized dextran, the NK4 protein was secreted at a higher amount for a longer time period in contrast to the conventional transfection of free plasmid DNA. The NK4-transfected Mf exhibited a stronger inhibition activity for in vitro growth of Meth-A fibrosarcoma cells. When injected intravenously into mice carrying a mass of Meth-A tumor cells, the Mf engineered were accumulated in the tumor tissue and showed significant anti-tumor activity. It is concluded that the Mf injected functioned as the natural carrier of tumor targeting for anti-tumor NK4 molecules, resulting in enhanced suppression of tumor growth at a high selectivity.
Introduction
Macrophages (Mf) play an important role in the natural surveillance system for tumor. Mf have an inherent ability to actively recognize the occurrence of tumor and prevent or suppress the tumor growth. 1 However, the Mf anti-tumor activity is not always strong enough to suppress the tumor growth. As one trial to resolve this issue, Mf should be activated for their anti-tumor function by any method. Since Mf themselves possess the inherent nature of tumor recognition, it is possible that they work as the natural carrier to target the tumor tissue, upon injecting intravenously. To provide Mf with an anti-tumor activity, it is one of the promising strategies to allow an anti-tumor gene to transfect. Therefore, it is necessary to develop the efficient technology of gene transfection. With the recent advent of genome sciences, genetic sequences related to diseases occurrence or the proliferation and differentiation of cells for tissue repairing have been elucidated. It is highly expected to manipulate the biological activity and function of cells at a genetic level for successful cell therapy. To achieve this genetic engineering of cells, virus carriers have been mainly used because of the high efficiency of gene transfection. [2] [3] [4] [5] [6] [7] [8] However, there are several problems to be resolved for the clinical applications, such as the antigenicity and toxicity of virus itself or the possibility of disease transfection. Therefore, efficient technology and methodology of gene transfection without virus vectors are highly expected. Several research trials with non-viral gene carriers of cationized polymers and liposomes have been performed, but do not always bring about results expected in terms of the transfection efficiency. [9] [10] [11] [12] The level of gene expression is not as high as that of viral carriers and the time period of expression is generally short. As the conventional procedure of gene transfection, a plasmid DNA is complexed with the non-viral carrier, and then added to the culture medium of cells for gene transfection. In this case, serum cannot be generally added to the culture medium, although it is essential to give cells the biological conditions good for culture. This is because the plasmid DNA-carrier complex often interacts with serum components, leading to the suppressed ability of gene transfection. To overcome the technical problem, a new transfection system has been introduced. 13 Cells are cultured on the surface of substrate, which was coated with the plasmid DNA-cationized dextran complex and gene transfected in the presence of serum (reverse transfection). The transfection method enhanced the level of gene transfection to a significantly high extent compared with the conventional one.
Hepatocyte growth factor (HGF) has been noted as a signal molecule that plays an important role in development, morphogenesis and regeneration of living systems. [14] [15] [16] [17] On the other hand, for malignant tumors, HGF plays a definitive role in invasive, angiogenic and metastatic behavior of tumor cells by way of the c-Met receptor. [18] [19] [20] [21] [22] Therefore, it is highly expected that the inhibition of interaction between HGF and the c-Met receptor effectively suppresses the malignant activity of tumors. On the basis of this concept, Date et al. 23 prepared an antagonist for HGF. The antagonist (NK4) is composed of the NH 2 -terminal hairpin domain and the subsequent four-kringle domains of a-subunit of HGF. The NK4 binds to the c-Met/HGF receptor, but does not induce the tyrosine phosphorylation of c-Met. 23 NK4 competitively inhibits some biological events driven by the HGF-Met receptor binding, including the invasion and metastasis of distinct types of tumor cells. 23, 24 Moreover, NK4 has an anti-angiogenic activity which is independent of the activity as an HGF antagonist. 25 The recombinant protein of NK4 has been used for tumor animal models to demonstrate the in vivo therapeutic feasibility and the blocking effect on HGF functions. [24] [25] [26] In addition, desired antitumor effects have been reported through the stable expression of NK4 gene in tumor cells with recombinant adenoviruses. [27] [28] [29] [30] [31] In this study, Mf were transfected by the NK4 plasmid DNA to give them a nature to secrete an antitumor NK4 protein. Genetic engineering of Mf was performed by the reverse transfection with the complex of a cationized dextran and NK4 plasmid DNA. In vitro inhibition of tumor cells growth was investigated by coculture with Mf genetically engineered. Following the intravenous injection into tumor-bearing mice, the in vivo anti-tumor activity of Mf engineered was evaluated. We examine feasibility of the reverse transfection method in the gene expression for Mf comparing with the conventional transfection of plasmid DNA complexed with the cationized dextran and Lipofectamine 2000 commercially available.
Results
Gene expression by spermine-dextran-plasmid DNA complexes Figure 1 shows the level of gene expression of sperminedextran-luciferase plasmid DNA complexes for Mf by the conventional and reverse methods. For the conventional transfection method, the expression level by the spermine-dextran-plasmid DNA complex was significantly higher than that of plasmid DNA with or without the Lipofectamine 2000 complex. In the presence of fetal calf serum (FCS), the level by the reverse transfection method was significantly higher than that by the conventional one. Figure 2 shows the time course of gene expression level of spermine-dextran-luciferase plasmid DNA complexes for Mf by the conventional and reverse methods. The level of gene expression by the reverse method of spermine-dextran complexes was high and lasted for a long time period compared with that by the conventional one. Figure 3 shows the confocal microscopic images of Mf at different time points after transfection with sperminedextran-plasmid DNA complexes by the conventional and reverse methods. When transfected by the reverse method, the plasmid DNA was localized in the cell nucleus at higher amounts even at a shorter time point than that by the conventional method while the nucleus localization lasted for longer time periods. w Po0.05; versus the expression level of free plasmid DNA at the corresponding time.
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In vitro anti-tumor properties of Mf genetically engineered by spermine-dextran-NK4 plasmid DNA complexes Figure 4 shows the time course of NK4 secretion of Mf transfected with spermine-dextran-plasmid DNA complexes by the conventional and reverse methods. When transfected with the spermine-dextran-plasmid DNA complexes by the reverse method, Mf secreted NK4 protein at significantly higher amounts even 2 days after transfection than those of non-transfected or transfected with free NK4 plasmid DNA. Moreover, the NK4 protein secretion lasted for longer time periods. Figure 5 shows the in vitro anti-tumor activity of Mf transfected by the reverse method of spermine-dextran-NK4 plasmid DNA complexes. Mf genetically engineered by the complex suppressed the in vitro proliferation of Meth-A cells to a significantly great extent compared with non-engineered naive cells.
In vivo anti-tumor activities of Mf genetically engineered by the reverse transfection method with spermine-dextran-NK4 plasmid DNA complexes Figure 6 shows the fluorescent microscopic image of tumor tissue 1 day after intravenous injection of green fluorescent protein gene (GFP)-transfected Mf to tumorbearing mice. It is apparent that Mf intravenously injected accumulated in the tumor tissue. Figure 7 shows the in vivo anti-tumor activity of Mf transfected by the reverse method of spermine-dextran-NK4 plasmid DNA complexes. The intravenous injection of Mf transfected with the spermine-dextran-NK4 plasmid DNA complexes by the reverse method tended to suppress the in vivo growth of tumor cells even at the early time period and exhibited significantly higher antitumor effect in vivo than that of non-transfected Mf.
Discussion
The present study clearly demonstrates that the delivery of NK4 plasmid DNA based on the natural potential of Mf to recognize the tumor tissue was effective in the in vivo anti-tumor therapy. This is the first report to show the tumor targetable therapy of Mf genetically engineered. This idea to therapeutically treat diseases by making use of the natural homing ability of cells, socalled gene-cell hybrid therapy, has been reported to demonstrate their therapeutic efficacy. Anti-tumor effect of M/ genetically engineered T Okasora et al Viral vectors have been mainly used for this purpose because of the high efficiency of gene transfection. However, there are scientific and ethical barriers to apply the viral transfection to the clinical treatment of patients. As one trial to tackle this issue, various nonviral carriers have been investigated. [9] [10] [11] [12] To enhance the level of gene expression, in addition to the research and development of gene carriers themselves, it is indispensable to improve the culture technology and methodology of cells for gene transfection. It is highly expected that the culture conditions always affect the biological state of cells, which strongly contribute to the level of gene transfection. We have demonstrated that the reverse transfection method gives cells good culture conditions, resulting in enhanced and prolonged gene expression with less cytotoxicity. 13 The efficacy of reverse transfection in gene expression was also confirmed in this study for the luciferase (Figures 1 and 2 ) and NK4 plasmid DNAs (Figure 4) . The higher efficiency of gene transfection can be explained in terms of the unique feature of reverse method. Mf are always cultured on the complex of plasmid DNA and spermine-dextran of non-viral carrier. It is likely that the localization of plasmid DNA close to cells enhances the possibility of cellular internalization of plasmid DNA, resulting in increased efficiency of gene transfection. In addition, the transfection culture can be performed in the presence of serum, which is a better condition for cell culture. It is apparent from Figure 3 that the plasmid DNA was localized in the nucleus of cells at higher amounts and for longer time periods. This may be also due to the efficient and continuous supply of plasmid DNA to cells.
Mf were targeted to the tumor tissue following their intravenous injection into mice carrying a tumor mass ( Figure 6 ). This is due to their natural tumor targetability. Mf genetically engineered showed the anti-tumor activity ( Figure 5 ). It is possible to consider several mechanisms of macrophages to kill tumor cells. First, macrophages transfected secreted anti-tumor NK4 proteins to directly kill Meth-A cells. Secondly, it is well known that macrophages naturally function as an effector cell to injure tumor cells by the secretion of various anti-tumor cytokines and the direct cell contact. 35 This inherent nature of macrophages would result in the anti-tumor effect. Taken together, it is likely that after intravenously injected, Mf genetically activated by the NK4 plasmid DNA of anti-tumor effect are naturally homed to the tumor tissue, resulting in the local and continuous secretion of NK4 protein at the tumor tissue to kill tumor cells. The amount of NK4 protein secreted increased with time up to 4 days. Thus, it is conceivable that this delayed secretion did not suppress the in vivo tumor growth at the early time period after injection of the cells.
Since Mf have an inherent ability to recognize and home to the site of inflammation and diseases other than the tumor tissue, the natural targeting by Mf as a drug carrier will be therapeutically available to various applications. This approach will be a promising cell therapy of the next generation, which can overcome the present problems to be resolved.
Materials and methods

Materials
Dextran with a weight-average molecular weight of 74 000 and spermine were purchased from Sigma Chemical Co., St Louis, MO, USA, Pronectin (Lot #: R1-7K002-A) was kindly supplied from Sanyo Chemical Industries, Kyoto, Japan. Other chemicals were obtained from Nacalai Tesque Inc., Kyoto, Japan and used without further purification.
Preparation of cationized dextran derivative
Spermine was introduced to the hydroxyl groups of dextran by a N,N 0 -carbonyldiimidazole activation method.
36 Spermine (1.87 Â 10 3 mg) and N,N 0 -carbonyldiimidazole (2.25 Â 10 2 mg) were added to 50 ml of dehydrated dimethyl sulfoxide containing 50 mg of dextran. Following agitation at 35 1C for 20 h, the reaction mixture was dialyzed against ultra-pure double-distilled water (DDW) for 2 days with a dialysis membrane (the cutoff molecular weight ¼ 12 000-14 000, Viskase Companies Inc., Willowbrook, IL, USA). Then, the solution dialyzed was freeze-dried to obtain the Anti-tumor effect of M/ genetically engineered T Okasora et al spermine-introduced dextran (spermine-dextran). When determined from the conventional elemental analysis, the molar percentage of spermine introduced to the hydroxyl groups of dextran was 17.9 mole%.
Preparation of plasmid DNA
The plasmid DNAs used were a pCMV vector 37 coding for a firefly luciferase gene (pCMV-luciferase), an NK4 gene (pCMV-NK4) and a green fluorescent protein gene (pCMV-GFP). The plasmid DNA was propagated in an E. coli (strain DH5a) and purified by QIAGEN plasmid Mega kit (Qiagen KK, Tokyo, Japan) according to the manufacturers' instructions. Both the yield and purity of the plasmid DNA were evaluated by UV spectroscopy (Ultrospec 2000, Pharmacia Biotech, Cambridge, UK). The absorbance ratio at wavelengths of 260-280 nm for plasmid DNA solution was measured to be between 1.8 and 2.0.
Preparation of polyion complexes
Polyion complexes were prepared by mixing an aqueous solution of spermine-dextran with that of plasmid DNA. Briefly, 4.0 mg of spermine-dextran was dissolved in 50 ml of double-distilled water and mixed with 50 ml of phosphate-buffered saline solution (10 mM, phosphatebuffered saline (PBS), pH 7.4) containing 2.5 mg of plasmid DNA, followed by leaving for 15 min at room temperature to obtain the polyion complex of sperminedextran and plasmid DNA at a nitrogen number of spermine-dextran/the phosphorus number of plasmid DNA ratio of 3.0. To complex the plasmid DNA with Lipofectamine 2000 (Invitrogen Corp., Carlsbad, CA, USA), 50 ml of Opti-MEM (Invitrogen Corp.) containing 5.0 mg of Lipofectamine was mixed with 50 ml of Opti-MEM containing 2.5 mg of plasmid DNA, followed by leaving for 15 min at room temperature.
Preparation and culture of Mf
Mouse peritoneal macrophages were isolated from 6-week-old female BALB/c mice (body weight ¼ 20 g, Shimizu Laboratory Supplies Co. Ltd., Kyoto, Japan) according to the conventional procedure previously reported. 38 Briefly, mice were injected aseptically with 2 ml of thioglycolate broth (BD Biosciences, San Jose, CA, USA) intraperitoneally. At 4 days after injection, 6.0 ml of Dulbecco's modified Eagle medium (DMEM) was intraperitoneally injected to the mice, and then the peritoneal cells were collected by syringe aspiration. After centrifugation (1000 r.p.m., 5 min, 4 1C), pelleted peritoneal cells were resuspended in DMEM supplemented with 15 vol% FCS, penicillin (50 U/ml) and streptomycin (50 U ml À1 ) and seeded on tissue culture plate (Corning Inc., Corning, NY, USA) at a density of 1 Â 10 6 cells cm
À2
. After incubating at 37 1C in 5% CO 2 , 95% air atmosphere for 2 h, the plate was washed thoroughly with DMEM to remove non-adherent cells. The adherent cells obtained were used as Mf for the following experiments.
Conventional gene transfection
Mf were seeded on each well of 12-well multi-dish culture plate (Corning Inc., USA) at a density of 5 Â 10 5 cells per well and cultured in 1 ml of DMEM medium with 15 vol% FCS for a week. Immediately after the medium was exchanged by the FCS-free DMEM medium, 100 ml of solution of the plasmid DNA complex with the cationized dextran or Lipofectamine 2000 or free plasmid DNA was added while the 3 h culture was performed for gene transfection in the presence or absence of FCS. Following the complete rinsing of cells with the FCS-free medium, cells were incubated in the DMEM medium with FCS further for 1, 3 and 5 days.
Reverse gene transfection
Succinic anhydride (90.1 mg) was added to 20 ml of 100 mg ml À1 gelatin solution in dimethylsulfoxide, followed by agitation at room temperature for 18 h to allow introducing the carboxyl groups to the amino groups of gelatin for anionization. When determined as the extent of amino groups decreased by the trinitrobenzene sulfonic acid method, 39 the molar amount of carboxylic groups introduced was 100 mole%.
The aqueous solution (200 ml) of the anionized gelatin (100 mg ml
À1
) and Pronectin (200 mg ml
) was placed into each well of 12-well multi-well culture plate, followed by leaving at 37 1C for 1 h to allow them to adsorb. Following PBS washing, the well was coated with the plasmid DNA-spermine-dextran complex containing 2.5 mg of plasmid DNA. Following incubation for 30 min, every well was washed with PBS. Then, Mf (5 Â 10 4 cells per well) were seeded on the complexcoated well, followed by cell culture in the DMEM medium with or without 15 vol% FCS for 1, 3 and 5 days.
Assay of gene expression
To assay the level of gene transfection, cells were washed with PBS once, lysed in 100 ml of cell culture lysis reagent (Promega Corp., Madison, WI, USA), transferred into a micro reaction tube, and the cell debris was separated by centrifugation (14 000 r.p.m., 20 min). Then, 100 ml of luciferase assay reagent (Promega Corp.) was added to 20 ml of supernatant while the relative light unit of the sample was determined by a luminometer (MicroLumatPlus LB 96 V, Berthold, Tokyo, Japan). The total protein of each well was determined by bicinchonic acid protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturers' instructions. The relative light unit was divided by the protein amount to normalize the influence of number variance of cells on the luciferase activity. Each experimental group was carried out three times independently. After the reverse transfection culture with the spermine-dextran-NK4 plasmid DNA complex for different time periods, the amount of NK4 protein secreted was measured by an IMMUNIS HGF EIA kit (Institute of Immunology Co. LTD., Tokyo, Japan) according to the manufacturers' instructions.
Microscopic observation of intracellular localization
To investigate the intracellular localization of plasmid DNA, the pCMV-luciferase was fluorescently labeled by using Label IT CX-Rhodamine Labeling Kit (Mirus, Madison, WI, USA) according to the manufacturers' instructions. After the conventional and reverse transfection cultures for different time periods with the complex of rhodamine-labeled plasmid DNA and the sperminedextran, cells were washed and fixed with 0.25 wt% glutaraldehyde solution in PBS, followed by staining nucleus with Hoechst 33342 (Molecular Probes, Eugene, OR, USA). Imaging data of cells were collected on an Olympus Fluoview FV300 confocal laser scanning Anti-tumor effect of M/ genetically engineered T Okasora et al microscope (Olympus, Tokyo, Japan) and processed with Adobe Photoshop 6.0 software (Adobe Systems Inc., San Jose, CA, USA).
In vitro antitumor activity of Mf genetically engineered
The in vitro antitumor activity of Mf was evaluated in terms of their suppression activity of tumor cells growth. Briefly, Mf (1 Â 10 6 cells) were genetically engineered by the reverse transfection culture with the complex of spermine-dextran-NK4 plasmid DNA in 6-well multiculture plate (COSTAR, Corning Inc.) as described above. Meth-A cells (1 Â 10 5 cells) were added to the Mf culture 3 h later. After coculture for 1, 3 and 6 days, the number of cells grown was counted. The experiment of each sample was performed for three wells. As controls, tumor cells were cultured with non-transfected, original Mf (1 Â 10 6 cells) or without Mf and the number was counted similarly.
In vivo therapeutic assay of Mf genetically engineered
Meth-A cells (1 Â 10 6 cells per mouse) suspended in 200 ml of PBS were subcutaneously inoculated into the back of BALB/C mice. Mf were genetically engineered by the reverse transfection with the complex of sperminedextran-NK4 plasmid DNA as described previously. When the tumor was grown to be the longest and the widest diameter of about 10 mm, tumor therapy with Mf genetically engineered was started. Mf genetically engineered were taken off with a rubber policeman, washed twice and resuspended in PBS. Then, 100 ml of Mf (5 Â 10 6 cells) suspended in PBS was intravenously injected via the tail vein of tumor-bearing mice. At different time periods after intravenous injection, the longest and widest diameter of tumor mass were measured with a caliper and the tumor volume was calculated by using the formula of (length) Â (width) 2 Â 1/2. 40 As controls, saline or non-transfected, original Mf was injected similarly.
Statistical analysis
Data were expressed as the mean±the s.d. of the mean. Data were analyzed by two-way analysis of variance, and then differences among means were analyzed using Fisher's PLSD multiple comparison test and significance was accepted at Po0.05.
